Zoetis Inc (NYSE:ZTS) was downgraded by stock analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report issued on Wednesday, AnalystRatingsNetwork reports. They currently have a $36.00 target price on the stock. Morgan Stanley’s price target would indicate a potential upside of 12.15% from the stock’s previous close. Zoetis Inc (NYSE:ZTS) stock opened at $31.27 in last trading session, and closed at $30.78, trading in the range of $30.72 – $31.45. The stock showed a negative weekly performance of -1.94%.
Mylan Inc (NASDAQ:MYL) announced that its U.S.-based subsidiary Mylan Pharmaceuticals has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk’s (NVO) Prandin, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The company received final approval from the FDA for its Abbreviated New Drug Application for this product, Mylan said. Mylan Inc (NASDAQ:MYL) shares closed at $44.48 on last trade day. Stock 52 week range is $27.66 – $46.73. Company’s market capitalization is $17.02 billion.
Piper Jaffray raised its price target for Actavis plc Ordinary Shares (NYSE:ACT) shares to $203 citing the depth of the company’s pipeline and the potential for a merger deal. Piper reiterates an Overweight rating on the stock. Actavis plc Ordinary Shares (NYSE:ACT) stock finished the last session at $180.76. The EPS of the stock remained -4.35. Company’s market capitalization is $31.46 billion.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN), a specialty pharmaceutical company, announced the issuance of a European patent (number 2341912) and Canadian patent (number 2,735,934) for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock closed at $9.95 in last trading session. The 52 week range of the stock is $4.45 – $10.12.
Leave a Reply